Other papers by authors:
Latest similar papers:
II Clinica Pediatrica e Servizio di Radiologia, Fondazione Policlinico, Mangiagalli e Regina Elena, Università degli Studi, Milano.
Acute acalculous cholecystitis (CAA) is very rare in children and it is usually related to infectious agents. We report 2 paediatric cases of CAA complicating hepatitis type A, with a favourable evolution with conservative treatment.
Banu Cakir,
Mehmet Teksam,
Nefise Cagla Tarhan,
Iclal Isiklar,
Nihal Uslu Tutar,
Figen Ozcay,
Mehmet Coskun,
Banu Bilezikci,
Beyhan Demirhan
Department of Radiology, Baskent University Faculty of Medicine, Fevzi Cakmak Cad. 10. sok., No: 45 Bahcelievler, Ankara 06490, Turkey.
Since the 1991 adoption of a comprehensive strategy to eliminate hepatitis B virus (HBV) transmission in the United States, the incidence of acute hepatitis B cases has declined steadily. Declines have been greatest among children born after the 1991 recommendations for universal infant hepatitis B vaccination were implemented. In 1995, the elimination strategy was expanded to include routine vaccination of all adolescents aged 11-12 years and, in 1999, to include children aged < or =18 years who had not been vaccinated previously. To describe the epidemiology of acute hepatitis B in children and adolescents in the United States, CDC analyzed notifiable disease surveillance data collected during 1990-2002 and data collected during 2001-2002 through enhanced surveillance of reported cases of acute hepatitis B in children born after 1990. This report summarizes the results of that analysis, which indicated that the rate of acute hepatitis B in children and adolescents decreased 89% during 1990-2002 and that racial disparities in hepatitis B incidence have narrowed. Many confirmed cases in persons born after 1990 occurred among international adoptees and other children born outside the United States. Continued implementation of the hepatitis B elimination strategy and accurate surveillance data to monitor the impact of vaccination are necessary to sustain the decline of acute hepatitis B among children.
Department of Urology, The Johns Hopkinds Medical Institutions, Baltimore, MD, USA.
Small atrophic prostate cancers on needle biopsy are rare and difficult to distinguish from benign atrophy on needle biopsy. We report on a study of 23 needle biopsy specimens with small foci of atrophic prostate cancer from the consult service of one of the authors. In 19 cancer cases the atrophic component was pure; in 4 cases it was dominant with a minor (<5%) nonatrophic cancer component. These atrophic cancers and 16 cases of florid benign atrophy on needle biopsy were examined by immunohistochemistry for alpha-methylacyl-CoA-racemase (AMACR). All cases of cancer and atrophy were verified immunohistochemically with antibodies to basal cells (34betaE12 and p63). AMACR staining were scored as 1+(5% to 25% of glands expressing AMACR), 2+(26% to 50% of glands expressing AMACR), or 3+(>50% of glands expressing AMACR). Positive staining was defined as staining above that of surrounding benign glands. AMACR was expressed in 69.6% of atrophic prostate cancers (3+, 11 cases; 2+, 3 cases; 1+, 2 cases); 30.4%(7 cases) of atrophic prostate cancer exhibited no AMACR expression. In the 4 cases with a few glands of ordinary (nonatrophic) prostate cancer, the nonatrophic cancer demonstrated more intense and a greater extent of AMACR staining. Fourteen cases (87.5%) of benign atrophy showed no AMACR expression. In 2 cases (12.5%) of benign atrophy, background immunostaining made it difficult to assess AMACR expression. We conclude that AMACR immunostaining alone is not sufficiently discriminatory in the differential diagnosis of atrophic prostate cancer versus benign atrophy. Atrophic prostate cancers are not as frequently or as strongly positive as ordinary prostate cancer. Using a panel of immunostains including AMACR, 34betaE12 and p63 (positive AMACR immunostaining along with negative basal cell markers) is recommended in the differentiation of atrophic prostate cancer and benign atrophy.
Universitatea Transilvania Braşov.
Liver damage, clinical manifest or inapparent is a frequent manifestation of infectious mononucleosis. This study has in view the forms and frequency of manifestation of liver damage in infectious mononucleosis. The retrospective study has included 115 patients with infectious mononucleosis, hospitalised in Braşov Infectious Diseases Hospital between 1.01.1998 and 31.12.2002. The enlargement of the liver as unique manifestation in liver damage was noticed in 27% of the cases; jaundice of the skin and sclerae in 10.4% of the cases; infectious mononucleosis hepatitis in 55.6% of the cases; and in 11.3% of cases high serum levels of GPT were noted. The levels of serum protein were also affected, low-grade increase of protein serum levels--18.2% of the cases, hypoalbuminemia--82.4% of cases and subunitary albumin/globulin ratio in 70.3% of the cases. All these levels might be indicators for liver damage.
